Jagsonpal Pharmaceuticals has successfully completed the allotment of 1,09,180 equity shares under its Employee Stock Option Plan 2022 (JPL ESOP 2022) to eligible employees on January 6, 2026. The allotment was executed by the company's Nomination and Remuneration Committee following the exercise of vested options by employees.

Share Capital Enhancement

The allotment has resulted in a significant increase in the company's paid-up share capital structure. The following table illustrates the capital enhancement:

ESOP Exercise Details

The newly allotted shares were issued at two different exercise prices based on the specific grant terms. The exercise pricing structure demonstrates the company's strategic approach to employee compensation:

Regulatory Compliance and Share Characteristics

The allotment was conducted in compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021. The newly issued equity shares carry the ISIN number INE048B01035 and rank pari-passu with existing equity shares in all respects.

The shares have been assigned distinctive numbers from 6,67,81,271 to 6,68,90,450 and are identical to existing shares without any lock-in restrictions. The company has listed its shares on both BSE Limited (Scrip Code: 507789) and National Stock Exchange of India Limited (Symbol: JAGSNPHARM).

Corporate Structure Impact

This ESOP allotment represents part of Jagsonpal Pharmaceuticals' ongoing employee retention and motivation strategy. The Employee Stock Option Plan 2022 was originally filed with the stock exchanges in July 2022, with BSE receiving the filing on July 26, 2022, and NSE on July 27, 2022. The successful execution of this allotment demonstrates the company's commitment to aligning employee interests with shareholder value creation through equity participation.

Jagsonpal Pharmaceuticals Limited has received a significant tax demand order from the Haryana State Tax authorities, totaling ₹1.52 crores for Financial Year 2021-22. The company disclosed this development on December 30, 2025, in compliance with SEBI listing regulations.

Tax Demand Details

The order was received on December 29, 2025, from the Office of the Deputy Commissioner of State Tax (SGST), Gurugram (East), Government of Haryana. The total demand comprises multiple components as outlined below:

Nature of Violations

The tax demand has been raised under section 73(9) of CGST/SGST Act, 2017 read with Section 20 of IGST Act, 2017. The order specifically addresses discrepancies identified in the company's GST compliance for Financial Year 2021-22.

The violations cited include:

• Mismatches of Input Tax Credit (ITC) appearing in GSTR-2A and GSTR-3B returns
• Tax liability discrepancies appearing in E-waybill vis-à-vis tax liability appearing in GSTR-1 Return
• Non-compliance with GST return filing requirements for the specified period

Company's Response Strategy

Jagsonpal Pharmaceuticals has outlined its response plan to contest the tax demand order. The company intends to file an appeal against the order before the concerned Appellate Authority along with the required pre-deposit for stay of the demand.

The order directs the company to make the payment in government treasury within 30 days of receipt. However, the company believes it has merits in the case and expects to challenge the demand through proper legal channels.

Financial Impact Assessment

The company has stated that it does not anticipate any material impact on its financials, operations, or other activities. Management believes the case has merit and expects to successfully contest the demand through the appellate process.

This disclosure was made pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, ensuring transparency with stakeholders regarding regulatory developments affecting the company.